0001209191-20-004301.txt : 20200121
0001209191-20-004301.hdr.sgml : 20200121
20200121172301
ACCESSION NUMBER: 0001209191-20-004301
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200116
FILED AS OF DATE: 20200121
DATE AS OF CHANGE: 20200121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Currie Mark G
CENTRAL INDEX KEY: 0001478244
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34620
FILM NUMBER: 20537074
MAIL ADDRESS:
STREET 1: C/O CYCLERION THERAPEUTICS, INC.
STREET 2: 301 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IRONWOOD PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001446847
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043404176
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 617-621-7722
MAIL ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-01-16
0
0001446847
IRONWOOD PHARMACEUTICALS INC
IRWD
0001478244
Currie Mark G
C/O IRONWOOD PHARMACEUTICALS, INC.
100 SUMMER STREET, SUITE 2300
BOSTON
MA
02110
1
0
0
0
Class A Common Stock
2020-01-16
4
M
0
8888
10.02
A
558160
D
Class A Common Stock
2020-01-16
4
S
0
8888
12.80
D
549272
D
Employee Stock Option (Right to Buy)
10.02
2020-01-16
4
M
0
8888
0.00
D
2020-02-02
Class A Common Stock
8888
0
D
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.74 to $12.91, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
This option, granted as an annual performance award, is presently exercisable in full.
/s/ Conor Kilroy, Attorney-in-Fact
2020-01-21